Recently, glucagon-like peptide 1 (GLP-1) receptor agonists drugs typically used to manage diabetes and support weight loss have gained attention for their potential effects on inflammatory conditions
Lecithin may also cause limited disruption of the fat cell membrane, though further research is needed
Sleep deprivation, which several studies have found to totally mess with GLP-1 secretion
The ADA emphasizes realistic goal-setting and the importance of combining pharmacotherapy with lifestyle modifications, including medical nutrition therapy and increased physical activity, to optimize outcomes
Ongoing clinical trials investigating strategies to improve anti-ErbB2 mAb therapy, such as ex vivo activated allogenic NK cells or macrophages engineered to express an anti-ErbB2 chimeric antigen receptor (CAR-M), may benefit from the enhanced anti-tumor immune responses induced by Cpt1a inhibition, potentially improving outcomes for tumors evading ADCC and resistant to Trastuzumab 87,88